The prevalence of occult hepatitis B virus infection in type 2 diabetes mellitus patients

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 7, 2008, Pages 668-673

  Demir, Mehmet ^a   Serin, Ender ^a   Göktürk, Savaş ^a   Ozturk, Nevin Akcaer ^a   Kulaksizoglu, Sevsen ^a   Yilmaz, Uǧur ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Diabetes mellitus; Occult hepatitis B virus infection; Prevalence

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; VIRUS DNA; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGAN TRANSPLANTATION; PREVALENCE; PRIORITY JOURNAL; SEROLOGY; SEX DIFFERENCE; VACCINATION; VIRUS DETECTION; BLOOD; CASE CONTROL STUDY; GENETICS; HETEROZYGOTE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; OPPORTUNISTIC INFECTION; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; BLOOD DONORS; CARRIER STATE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS;

EID: 60049088470     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f55e1e     Document Type: Article

References (33)

1. Torbenson M, Thomas DL. Occult hepatitis B infection. Lancet Infect Dis 2002; 2:479-486.
2. Saraswat S, Banerjee K, Chaudhury N, Mahant T, Khandekar P, Gupta RK, Naik S. Posttransfusion hepatitis type B following multiple transfusions of HBSAg-negative blood. J Hepatol 1996; 25:639-643.
3. Feitelson M, Lega L, Guo J, Resti M, Rossi ME, Azzari C, et al. Pathogenesis of posttransfusion viral hepatitis in children with beta-thalassemia. Hepatology 1994; 19:558-568.
4. Reherman B, Ferrari C, Pasquinelnelli C, Chisari FV. The hepatitis B virus persists for decades after patients recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2:1104-1108.
5. Pao CC, Yang WL, Wu SY, Lai GM, Shih LY, Sun CF, Liaw YF. Presence of hepatitis B virus DNA in serum of surface-antigen-seronegative immunocompromised patients. J Clin Microbiol 1987; 25:449-451.
6. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 36:869-875.
7. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006; 35:14-20.
8. Unger RH, Foster DW. Diabetes mellitus. In: Wilson JD, Foster DW, editors. Williams' textbook of endocrinology. 8th ed. Philadelphia: Saunders; 1992. pp. 1255-1333.
9. Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polimophonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992; 15:256-260.
10. Matsuo M. Association between diabetes mellitus and hepatocellular carcinoma: results of a hospital- and community-based case-control study. Kurume Med J 2003; 50:91-98.
11. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001; 96:2462-2467.
12. Besisik F, Karaca C, Akyüz F, Horosanli S, Onel D, Badur S, et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 2003; 38:506-510.
13. Torbenson M, Kannangal R, Astemborkski J, Strathdee SA, Vlahov D, Thomas DL. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 2004; 39:51-57.
14. Toyoda H, Hayashi K, Murakami Y, Honda T, Katano Y, Nakano I, et al. Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. J Med Virol 2004; 73:195-199.
15. Pawlotsky JM, Bastie A, Hezode C. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays. J Virol Methods 2000; 85:11-21.
16. Mistik R, Balik I. Tü rkiyede viral hepatitlerin epidemiyolojik analizi. Viral Hepatit 2003, Viral hepatit ile savasim derneǧi yayini, Istanbul, 10-55.
17. Pahsa A, Ü zsoy MF, Altunay H, Koçak N, Ekren Y, Ç avusoǧlu Ş. ?Istanbulda hepatit B ve C seoprevelansi. Gülhane Tip Derg 1999; 41:325-330.
18. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003; 37:1172-1179.
19. Tabor E, Purcell RH, Gerety RJ. Primate animal models and titered inocula for the study of human hepatitis A, hepatitis B, and non-A, non-B hepatitis. J Med Primatology 1983; 12:305-318.
20. Jilg W, Sieger E, Zavhoval R, Schatzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker to hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 1995; 23:14-20.
21. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and 'silent' HBV co-infection: two main risk factors for a more severe liver disease. J Med Virol 2001; 64:350-355.
22. Chaudhuri V, Nanu A, Panda SK, Chand P. Evaluation of serological screening of blood donors in India reveals a lack of correlation between anti-HBc titer and PCR-amplified HBV DNA. Transfusion 2003; 43: 1442-1448.
23. Besişik F, Akyüz F. Okult HBV enfeksiyonu. In: Cakaloǧlu Y, Ökten A, editors. Türkiye'de viral hepatitlerin epidemiyolojik analizi. 1st ed. Istanbul: Viral Hepatit Savas Dernegi; 2003. pp. 77-89.
24. Pozzilli P, Signore A, Leslie RDG. Infections, immunity and diabetes. In: Pickup J, Willams G, editors. Text book of diabetes. Oxford: Blackwell Science Ltd.; 1997. pp. 1231-1241.
25. Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol 2005; 42:480-485.
26. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 93:230-239.
27. Yotsunayanagi H, Yasuda K, Iino S, Moriya K, Shintani Y, Fujie H, et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 1998; 27:1377-1382.
28. Yang HL, Lu SN, Liaw YF. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Eng J Med 2002; 347:168-174.
29. Shintani Y, Yotsuyanagi H, Moriya K, Fujje H, Tsutsumi T, Takayama T, et al. The significance of hepatitis B virus DNA detected in hepatocellular carcinoma of patients with hepatitis C. Cancer 2000; 88:2478-2486.
30. Yu MC, Yuan JM, Ross RK, Govindarajan S. Presence of antibodies to the hepatitis B surface antigen is associated with excess risk for hepatocellular carcinoma among non-Asians in Los Angeles County. California Hepatol 1997; 25:226-228.
31. Sheu JC, Huang GT, Shih LN. Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology 1992; 103:1322-1327.
32. Brechot J, Jaffredo F, Lagorce D. Impact of HCV, HBV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of European concerted action. J Hepatol 1998; 29:173-183.
33. Ahn SH, Park YN, Park JY, Chang HY, Lee JM, Shin JE, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005; 42:188-194.